News and Events
Stay abreast of our latest news, updates, and conferences we will be attending
Adaptin Bio, Inc., a Lucius Partners Portfolio Company, Completes Alternative Public Offering (APO) and Closes $7.7 Million Private Placement
April 07, 2025 12:25 ET CHARLOTTE, N.C.--(GLOBAL NEWSWIRE)-- Adaptin Bio, Inc. (“Adaptin” or the “Company”), a biotechnology company focused on developing precision cancer therapies with improved delivery to the brain and other tissues, announced today the successful completion of a reverse merger of a wholly owned subsidiary of Unite Acquisition 1 Corp. with and into Adaptin, with Adaptin continuing as the surviving entity. Adaptin Bio expects to trade on the OTC Markets. In connection with the merger, Adaptin completed a private placement for the issuance and sale of 1,400,342 shares of its common stock and accompanying Series A warrants and Series B warrants. The Series A warrants will have a 1-year term, and an exercise price of $4.40 per common share. The Series B warrants will have a 5-year term, and an exercise price of $6.60 per common share. The merger also triggered the conversion of $1.5 million of promissory [...]
Adaptin Bio Announces FDA Clearance of IND Application for APTN-101 in Glioblastoma
APTN-101 is a novel BRiTE therapeutic targeting the most aggressive form of brain cancer Unique mechanism of action of APTN-101 will be evaluated in Phase 1 first-in human clinical trial in glioblastoma CHARLOTTE, N.C.--(BUSINESS WIRE)-- Adaptin Bio, a biotechnology company focused on developing precision cancer therapies with improved delivery to the brain and other tissues, has emerged from stealth today with the announcement that FDA has cleared an Investigational New Drug (IND) application for its APTN-101 program in glioblastoma (GBM), the most common and aggressive primary brain tumor. The clearance will enable the initiation of a first-in-human Phase 1 clinical trial to evaluate this investigational candidate in GBM. APTN-101 is a proprietary BRiTE (Brain Bispecific T cell Engager) therapeutic designed to target EGFRvIII, a specific protein linked to aggressive brain tumors. In preclinical studies, APTN-101 has shown a greater than 7-fold increase in distribution into the brain, with significant potential [...]
To come
Download logos and images here. On most browsers right (or control) click to download the image:
Icon
Branding image
To come
